Casey Tansey Purchases 35,572 Shares of Mobia Medical (NASDAQ:MOBI) Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 35,572 shares of the stock in a transaction dated Thursday, August 13th. The shares were bought at an average cost of $11.51 per share, for a total transaction of $409,433.72. Following the acquisition, the director owned 268,904 shares in the company, valued at $3,095,085.04. The trade was a 15.25% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Mobia Medical Stock Performance

Shares of MOBI stock opened at $11.42 on Thursday. The firm has a 50 day moving average of $12.38. Mobia Medical, Inc. has a twelve month low of $10.19 and a twelve month high of $15.29. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80. The company has a market cap of $380.17 million and a P/E ratio of -0.59.

Mobia Medical (NASDAQ:MOBI) last announced its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million during the quarter. The company’s quarterly revenue was up 102.4% compared to the same quarter last year. On average, analysts forecast that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Bank of America began coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 target price for the company. Weiss Ratings began coverage on shares of Mobia Medical in a report on Wednesday, August 12th. They set a “sell (e-)” rating for the company. Wall Street Zen upgraded Mobia Medical from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. Finally, BTIG Research reissued a “buy” rating and set a $19.00 price objective on shares of Mobia Medical in a research report on Wednesday, August 12th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.